AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34320709
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment only (Control)
Trial: 32723193
Drug: 350 mg dose
RxNorm normalized name: aminophylline 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg dose of herbal supplement (70:30 blend of Rhaponticum carthamoides extract and Rhodiola rosea extract)
Trial: 32723193
Drug: 175 mg dose
RxNorm normalized name: theophylline 175 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 175 mg dose of herbal supplement plus 175 mg of maltodextrin
Trial: 38805733
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (placebo)
Trial: 36129733
Drug: Endocare (virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocare (virtual reality digital treatment)
Trial: 38325988
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (MT) alone
Trial: 32620104
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg)
Trial: 34339370
Drug: STRAP (Style
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STRAP (Style Transfer Augmentation)
Trial: 36456021
Drug: Inulin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inulin (20 g/day of powdered supplement dissolved in water)
Trial: 32796410
Drug: Kyphosis exercise
RxNorm normalized name: Kyprolis
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Kyphosis exercise and posture training intervention (twice weekly for 3 months)
Trial: 35339397
Drug: Homeopathic medicine
RxNorm normalized name: Homeopathic medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic medicine Natrum muriaticum LM2
Trial: 36045877
Drug: IM progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IM progesterone in oil (25 mg daily)
Trial: 36045877
Drug: IM progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IM progesterone in oil (50 mg daily)
Trial: 36045877
Drug: Progesterone suppository
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone suppository (400 mg daily)
Trial: 36045877
Drug: Progesterone suppository
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone suppository (800 mg daily; 400 mg twice daily)
Trial: 36045877
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone suppository groups
Trial: 34664221
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (VD3) 4000 IU daily for 3 months
Trial: 32770661
Drug: 75 grams
RxNorm normalized name: vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 grams of oral glucose + 6 grams of oral sodium chloride (NaCl) load
Trial: 35916700
Drug: Full imi
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full imi intervention web application (treatment)
Trial: 35485687
Drug: Oral tablets
RxNorm normalized name: digoxin 0.1875 MG Oral Tablets
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets of zinc sulfate twice a day for 3 months
Trial: 32331091
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray (56-84 mg twice-weekly for 4 weeks) + oral antidepressant (AD)
Trial: 32331091
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray (56-84 mg once-weekly or once-every-other-week) + oral antidepressant (AD)
Trial: 38330980
Drug: Intracytoplasmic sperm
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracytoplasmic sperm injection (ICSI)
Trial: 35737923
Drug: Bicalutamide 150
RxNorm normalized name: bicalutamide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 150 mg daily
Trial: 35916128
Drug: Lisinopril (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (up to 40 mg)
Trial: 35916128
Drug: Candesartan (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (up to 32 mg)
Trial: 35042738
Drug: Fluoxetine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine treatment for 26 weeks
Trial: 34918951
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 26 weeks
Trial: 32643358
Drug: QLB dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLB dexmedetomidine intravenous (QD IV)
Trial: 32228330
Drug: 5-mg fast-release
RxNorm normalized name: BAYER Fast Release Extra Strength 500 MG Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg fast-release melatonin
Trial: 35640529
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg oral THC
Trial: 35996073
Drug: Neostigmine (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.04 mg/kg) and atropine (0.02 mg/kg) intravenously
Trial: 32838813
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of oral ondansetron following ED visit
Trial: 32838813
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of oral ondansetron
Trial: 32289193
Drug: Well-being therapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Well-being therapy (WBT)
Trial: 33710724
Drug: PECS II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PECS II block with 30 mL 0.25% bupivacaine
Trial: 33710724
Drug: RIB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIB with 30 mL 0.25% bupivacaine
Trial: 616795279
Drug: Methylprednisolone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 0.5 mg/kg/tpd with beta-lactam plus macrolide
Trial: 33961943
Drug: Hydroxychloroquine 300
RxNorm normalized name: hydroxychloroquine 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 300 mg once daily for 6 months
Trial: 39463187
Drug: Aripiprazole once-monthly
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole once-monthly 400 mg (AOM 400)
Trial: 33531062
Drug: Weekly sweep
RxNorm normalized name: sheep wool preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly sweep
Trial: 37264472
Drug: Buprenorphine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine treatment
Trial: 34033621
Drug: Caffeine (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (4.5 mg·kg‐1)
Trial: 32851257
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone
Trial: 34674750
Drug: Bamlanivimab (4200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bamlanivimab (4200 mg)
Trial: 32467502
Drug: NOACs vs
RxNorm normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOACs vs Warfarin
Trial: 33719027
Drug: Ferric citrate
RxNorm normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric citrate hydrate (FC) 1000 mg/day
Trial: 33719027
Drug: Ferric citrate
RxNorm normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric citrate hydrate (FC) 500 mg/day
Trial: 33719027
Drug: Sodium ferrous
RxNorm normalized name: docusate sodium / ferrous fumarate Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ferrous citrate (SF) 100 mg/day
Trial: 35341944
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of Longevity™, a proprietary essential oil blend
Trial: 33624184
Drug: Reldesemtiv 150
RxNorm normalized name: Reldesemtiv
DrugBank: Reldesemtiv (DB15256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reldesemtiv 150 mg
Trial: 33624184
Drug: Reldesemtiv 450
RxNorm normalized name: Reldesemtiv
DrugBank: Reldesemtiv (DB15256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reldesemtiv 450 mg
Trial: 33624184
Drug: Reldesemtiv (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reldesemtiv (highest peak plasma concentration quartile, Cmax > 3.29 μg/mL)
Trial: 35724774
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg avasopasem
Trial: 35724774
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg avasopasem
Trial: 32129851
Drug: Targeted use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted use of ACTs and taking the correct dose, in addition to experience with RDT
Trial: 33234634
Drug: GR1501 (IL-17A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR1501 (IL-17A targeted monoclonal antibody)
Trial: 39637881
Drug: Filgotinib 100
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Filgotinib 100 mg
Trial: 39521467
Drug: Standard oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oxygen therapy
Trial: 39289685
Drug: Oral synbiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral synbiotics
Trial: 37452140
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg
Trial: 616852759
Drug: High-frequency fulguration
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency fulguration combined with 5% imiquimod cream
Trial: 616852759
Drug: High-frequency fulguration
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency fulguration combined with intramuscular injection of Bacillus Calmette-Guerin polysaccharide nucleic acid
Trial: 35771569
Drug: BG00011 56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG00011 56 mg once-weekly subcutaneous
Trial: 34236302
Drug: Lidocaine 5%
RxNorm normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 5% patch (Laboratorios Gebro Pharma, SA)
Trial: 34236302
Drug: Versatis 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Versatis 5% lidocaine patch (Grünenthal)
Trial: 34808678
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment (Control)
Trial: 32892756
Drug: Standardised lunch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised lunch providing 1.5 g/kg body mass of carbohydrate
Trial: 32383574
Drug: Motor program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motor program activating therapy (Group 2)
Trial: 33616765
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (G2) received treatment with OS and LED therapy (device turned off)
Trial: 33616765
Drug: OS associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OS associated with LED therapy (G5) once a week
Trial: 33616765
Drug: OS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OS therapy plus infrared LED (G6) two sessions per week
Trial: 32761980
Drug: Zembrin® (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zembrin® (25 mg)
Trial: 35833120
Drug: Bifidobacterium animalis
RxNorm normalized name: Bifidobacterium Animalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium animalis subsp. lactis MH‐02, 2 × 10^9 colony‐forming units per packet, once daily for 7 days
Trial: 32649493
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg twice daily for 7 days after 3 consecutive days of bleeding or spotting
Trial: 35671033
Drug: Metformin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin with comorbidity
Trial: 35671033
Drug: Metformin without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin without comorbidity
Trial: 32302798
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with dementia undergoing oral and maxillofacial surgery
Trial: 35244704
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and nicotine patch
Trial: 33077259
Drug: Clear cell
RxNorm normalized name: Umbilical Cord Blood Mononuclear Cells Conditioned Medium
DrugBank: Human umbilical cord blood mononuclear cell-conditioned medium (DB15724)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear cell (CC) OC
Trial: 32770640
Drug: Secukinumab 150
RxNorm normalized name: secukinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 150 mg with a loading dose (LD group)
Trial: 37574132
Drug: Alectinib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alectinib 600 mg twice daily
Trial: 35275991
Drug: Crizotinib 250
RxNorm normalized name: crizotinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib 250 mg
Trial: 33481455
Drug: Inpatient physical
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient physical rehabilitation (4-week hospitalization with physical, occupational, and speech therapy)
Trial: 34904190
Drug: Etomidate (0.2-0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.2-0.3 mg/kg)
Trial: 32286687
Drug: Adjuvant trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant trastuzumab emtansine (T-DM1) 3.6 mg/kg intravenously every 3 weeks
Trial: 32286687
Drug: Trastuzumab 6
RxNorm normalized name: Trastuzumab 60 mg powder for solution for infusion vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab 6 mg/kg intravenously every 3 weeks
Trial: 35685611
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) with propofol and remifentanil
Trial: 33220395
Drug: E +
RxNorm normalized name: Perle +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E + RT (oral erlotinib 150 mg/d for 2 years or until disease progression or intolerable toxicity and RT 200 cGy/d, 5 d/wk for 6 weeks)
Trial: 32550915
Drug: SC144 (gp130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC144 (gp130 inhibitor)
Trial: 32058426
Drug: Cariprazine low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cariprazine low-dose (0.25-0.5 mg/day)
Trial: 32058426
Drug: Cariprazine high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine high-dose (1.5-3.0 mg/day)
Trial: 35210111
Drug: Biodegradable gel
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biodegradable gel containing hyaluronic acid and berberine hydrochloride
Trial: 33246499
Drug: Convalescent plasma
RxNorm normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent plasma (2 units of 200 to 250 mL within 12 hours after randomization, with a second administration of 2 units 24 to 36 hours after the first administration)
Trial: 35012326
Drug: Ketamine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.8 mg/kg i.v. over 40 minutes) plus psychological therapy
Trial: 35012326
Drug: Ketamine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.8 mg/kg i.v. over 40 minutes) plus alcohol education
Trial: 35012326
Drug: Saline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline plus psychological therapy
Trial: 33823966
Drug: Drug-associated cue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-associated cue exposure in abstinent MUD group
Trial: 33823966
Drug: Scrambled trials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scrambled trials (no drug-associated cues) in abstinent MUD group
Trial: 35666728
Drug: Bronchodilators
RxNorm normalized name: ANTIASTHMA/BRONCHODILATORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilators
Trial: 36963200
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment regimens
Trial: 34115380
Drug: Monthly fremanezumab
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly fremanezumab (675 mg for CM, 225 mg for EM)
Trial: 616173846
Drug: Trimetazidine (TR)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TR) 70 mg/d bid for 3 months, then Ranolazine (RN) 1000 mg/d bid for 3 months
Trial: 616173846
Drug: Ranolazine (RN)
RxNorm normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranolazine (RN) 1000 mg/d bid for 3 months, then Trimetazidine (TR) 70 mg/d bid for 3 months
Trial: 34564022
Drug: 600 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/kg betaine (group B)
Trial: 34564022
Drug: 1,200 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg/kg betaine (group C)
Trial: 34564022
Drug: 1,800 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,800 mg/kg betaine (group D)
Trial: 39067509
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray
Trial: 32082606
Drug: Oxytocin nasal
RxNorm normalized name: oxytocin Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin nasal spray
Trial: 33902551
Drug: SA (alumina
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SA (alumina sandblasted and acid‐etched) implants
Trial: 37657525
Drug: MTX monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX monotherapy
Trial: 34533841
Drug: Biperiden (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden (4 mg)
Trial: 36169608
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group 1: diprospan combined with mucopolysaccharide polysulphate cream
Trial: 36169608
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group 2: isotopic phosphorus‐32 dressing combined with mucopolysaccharide polysulphate cream
Trial: 36169608
Drug: Treatment Group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Group: isotopic phosphorus‐32 dressing combined with diprospan and mucopolysaccharide polysulphate cream
Trial: 36503505
Drug: Negative Pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative Pressure Wound Therapy (NPWT)
Trial: 32401733
Drug: Non-NPWT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-NPWT treatment (petrolatum gauze and Bogota bag)
Trial: 35997729
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (IMRT with cisplatin, 100 mg/m2 every 3 weeks for 3 cycles) (n=169)
Trial: 35997729
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (n=169)
Trial: 34930386
Drug: Posttreatment CA-125
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posttreatment CA-125 level > 10 U/ml
Trial: 34930386
Drug: Posttreatment CA-125
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posttreatment CA-125 level ≤ 10 U/ml
Trial: 33634319
Drug: Standard MNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard MNP (12.5 mg iron)
Trial: 32749579
Drug: Carbonated water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbonated water (250 ml)
Trial: 32749579
Drug: Plain water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain water (250 ml)
Trial: 33326891
Drug: Antidepressant medications
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medications
Trial: 34240125
Drug: hs‐cTnI at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs‐cTnI at 10 ng/L
Trial: 34240125
Drug: hs‐cTnT at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs‐cTnT at 10 ng/L
Trial: 37865138
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone (XR-NTX)
Trial: 35680097
Drug: Placebo (balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (balanced salt solution)
Trial: 35349129
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of dexamethasone
Trial: 32056766
Drug: Peer- or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer- or clinician-led group behavioral treatment for 20 weeks
Trial: 36014767
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no glucoraphanin or alliin supplements)
Trial: 37488627
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy